Select Page

The Vaxzevria (AstraZeneca) vaccine, just like all other COVID-19 vaccines, was tested extensively before it entered the market. Vaxzevria (AstraZeneca) is not associated with a rise in the overall risk for blood clots (thromboembolic conditions). Moreover, the symptoms in case of a blood clot can be treated very well if detected in time; the vaccine is effective and well suited to prevent severe progressions of COVID-19. If side effects persist or occur (such as dizziness, headaches, vision impairment, shortness of breath, pain in arms or legs etc.), please consult a doctor to rule out thrombosis. National expert committees have spoken in favour of the use of the Vaxzevria (AstraZeneca) vaccine as its effectiveness is clearly documented and it thus saves lives every day.
Please note that the AstraZeneca vaccine is no longer available in Austria since 1 December 2021, and will also not be reordered.